Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with rare diseases and cancer. The company has a unique portfolio of product candidates, including etigilimab and alvelestat, which target specific unmet medical needs in oncology and respiratory conditions, primarily in the U.S. and Europe.
Mereo BioPharma aims to generate revenue through the commercialization of its drug candidates once they receive regulatory approval. The company has a strong focus on rare diseases, which often have less competition and higher pricing power due to the lack of available treatments. Its strategic partnerships with larger pharmaceutical companies may also provide additional revenue streams through milestone payments and royalties.
Clinical trial results for etigilimab and alvelestat, particularly Phase 2 and Phase 3 outcomes
Regulatory approvals from the FDA or EMA for its drug candidates
Partnership announcements or licensing deals with larger pharmaceutical companies
Market sentiment around rare disease therapies and biotech sector trends
Regulatory changes impacting drug approval processes
Technological disruption in drug development methodologies
Emergence of new therapies for the same indications from competitors
Potential for larger pharmaceutical companies to dominate the rare disease market
High cash burn rate leading to potential liquidity issues if funding is not secured
Dependence on external funding sources for R&D
low - Mereo operates in a niche market focused on rare diseases, which are less sensitive to economic cycles compared to broader healthcare spending.
Interest rates can affect Mereo's cost of capital and funding for R&D, but the company currently has no debt, minimizing direct impact on financing costs.
minimal - The company has no debt, reducing exposure to credit conditions.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has exhibited significant volatility, particularly given its clinical stage and reliance on trial outcomes.